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Noninherited antibiotic resistance is a phenomenon whereby a subpopulation of genetically identical bacteria displays pheno-
typic tolerance to antibiotics. We show here that compared to Escherichia coli, the clinically relevant genus Burkholderia dis-
plays much higher levels of cells that tolerate ceftazidime. By measuring the dynamics of the formation of drug-tolerant cells
under conditions that mimic in vivo infections, we show that in Burkholderia bacteria, oxygen levels affect the formation of
these cells. The drug-tolerant cells are characterized by an anaerobic metabolic signature and can be eliminated by oxygenating
the system or adding nitrate. The transcriptome profile suggests that these cells are not dormant persister cells and are likely to
be drug tolerant as a consequence of the upregulation of anaerobic nitrate respiration, efflux pumps, -lactamases, and stress
response proteins. These findings have important implications for the treatment of chronic bacterial infections and the method-
ologies and conditions that are used to study drug-tolerant and persister cells in vitro.
In a genetically identical population of bacteria, high doses ofantibiotics kill most but not all individuals. On reculturing, the
surviving bacteria give rise to a population that is similarly suscep-
tible to antibiotics. This phenomenon was first identified almost
70 years ago (1) and has been termed noninherited antibiotic re-
sistance. The molecular mechanisms that enable cells to resist su-
pra-MIC doses of antibiotics are not fully elucidated. In some
cases, drug tolerance is a consequence of the formation of dor-
mant persister cells (2, 3). There is now evidence linking bacterial
drug tolerance and persister cell formation with chronic infec-
tions, which are refractory to treatment with antibiotics (4–6).
Many different explanatory hypotheses explaining bacterial
drug tolerance and persister cell formation have been proposed (3,
7, 8). One prominent idea is that there are two phenotypically
distinct cell states between which bacteria switch at constant rates
(9, 10). However, this and other hypotheses are derived mainly
from experiments with Escherichia coli grown in aerated broth
cultures. This does not reflect the conditions under which bacteria
that establish chronic disease encounter in vivo during antibiotic
treatment. Chronic infections are often characterized by the for-
mation of biofilms (11, 12) or the existence of bacteria in struc-
tures, such as granulomas. For example, Mycobacterium tubercu-
losis, the causative agent of tuberculosis, forms granulomas in the
lungs (13), and Burkholderia pseudomallei, the causative agent of
melioidosis, forms granulomas and abscesses in various organs of
infected mice and humans (14–16). In these structured environ-
ments, bacteria are subjected to nutrient-starved low-oxygen con-
ditions, and studies in several bacterial species have shown that
their metabolic state is more similar to that of stationary-phase
bacteria than to that of log-phase bacteria grown in the laboratory
(17, 18).
In this study, we investigated the formation of drug-tolerant
cells by B. pseudomallei and its close but nonpathogenic relative
Burkholderia thailandensis. Both bacteria can be readily isolated
from soil or stagnant water in many tropical countries and can
persist in the environment. For example, B. pseudomallei is re-
ported to survive for extended periods in moist clay soil, in water
at different pH or salt concentrations, or even in nutrient-free
water for up to 16 years (19–22). B. pseudomallei and B. thailand-
ensis share highly syntenic chromosomes (23) and form a mono-
phyletic clade (24), and B. thailandensis is frequently used as a
surrogate for B. pseudomallei.
Here, we show that B. pseudomallei and B. thailandensis form
drug-tolerant cells at a high frequency. Using transcriptional pro-
filing, in vivo-like experimental conditions, and mathematical
modeling, we demonstrate that the formation of these drug-toler-
ant cells is affected by oxygen and nitrate and that these cells adopt
an anaerobicmetabolism. In accordancewith thismodel, we show
that increasing oxygen levels results in a decrease in the number of
drug-tolerant cells in vitro. These findings provide important new
insights into the mechanisms of formation of drug-tolerant cells
during disease.
MATERIALS AND METHODS
Bacterial strains and culture conditions.All bacterial strains are listed in
Table S1 in the supplemental material. B. thailandensis strain E264 was
mainly used throughout the study. Unless stated otherwise, the bacteria
were grownwith aeration at 200 rpm in Luria-Bertani broth (LB) at 37°C.
Anaerobic incubation was performed in an anaerobic chamber (DG 500
workstation; Don Whitley Scientific). Ceftazidime (catalog no. C3809;
Sigma-Aldrich) was used at 400 g/ml by preparing dilutions from a
freshly prepared stock at 10 mg/ml active component in 0.1 N NaOH.
Ciprofloxacin (catalog no. 17850; Sigma-Aldrich)was used at 40g/ml by
preparing dilutions from a 1-mg/ml stock solution in 0.1 NNaOH, which
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was stored at20°C. Metronidazole (catalog no. M1547; Sigma-Aldrich)
was used at 100 g/ml.
Construction of a narG mutant. An in-frame deletion mutant was
constructed using suicide plasmid-containing regions homologous to the
regions upstream and downstream of the target genes (25). The amplified
DNA fragments used for constructing the suicide plasmid derivatives
were generated by recombinant PCR (26). Briefly, 600-bp upstream and
downstream fragments of the narG (BPSL2309) gene of B. pseudomallei
strain K96243 were PCR amplified using two different primer combina-
tions: p2309-1 and p2309-2 (upstream), and p2309-3 and p2309-4
(downstream), with K96243 genomic DNA as a template. Both the
p2309-2 and pD2309-3 primers contained complementary sequences,
containing a HindIII restriction site and a start and stop codon of the
target gene to allow for efficient ligation of both flanking regions of the
target gene by fusion PCR. The resulting PCR product (1.2 kb) was cloned
into the suicide vector pDM4 via its NdeI andXbaI sites and confirmed by
PCR using the upstream (p2309-1) and downstream (p2309-4) primers.
The pDM4 derivative was transformed into E. coli strain S17 pir and
conjugated into B. pseudomallei by mating. Recombinant B. pseudomallei
strains were selected on LB agar plates supplemented with 100 g/ml
gentamicin to select against the donor strain and 100 g/ml chloram-
phenicol to select for B. pseudomallei transconjugants carrying the pDM4
constructs integrated into the chromosome. To generate in-frame dele-
tion mutants, overnight cultures of the transconjugants were plated onto
LB agar plates containing 10% (wt/vol) sucrose. Chloramphenicol-sensi-
tive colonies were analyzed for a deletion of the target gene. Confirmation
of the mutants was performed by two PCRs (see Fig. S7A in the supple-
mental material), using primers binding to an internal 300-bp region of
the gene (absent in the mutant) and a second PCR using primers binding
300 bp upstream and downstream of the target gene (BPSL2309).
Drug tolerance under hypoxic conditions. The fraction of drug-tol-
erant cells in a population was determined by exposing the bacterial cul-
tures to antibiotics using a concentration of100 the MIC for ceftazi-
dime (400 g/ml for strain E264) or 10 the MIC for ciprofloxacin (40
g/ml for strain E264), concentrations at which the antibiotics were still
soluble. In order to mimic slow-growing hypoxic in vivo conditions, the
assay was carried out using stationary-phase cultures, which were distrib-
uted into 24-well plates (nonpyrogenic polystyrene; Corning) using a
standard volume of 1 ml per sample containing approximately 108 CFU
each. When necessary, 20 mM sodium nitrate was added to the appropri-
ate wells of the 24-well plate. The assay plates were incubated statically at
37°C for 24 h in an aerobic incubator, unless stated otherwise. At the end
of the incubation period, the samples were transferred to centrifuge tubes
and centrifuged for 4 min at maximum speed. The antibiotic-containing
supernatant was removed, and the cells were resuspended in 1ml fresh LB
medium.CFUcountswere performedby spot plating serial dilutions onto
LB agar plates. The survival frequency was defined as the number of cells
that survived the antibiotic treatment divided by the input CFU. Killing
curve analyses were performed in a similar manner by preparing 24 1-ml
aliquots of bacteria in an antibiotic solution in a 24-well plate that was
incubated statically at 37°C. One-milliliter samples were removed at the
indicated time points and processed as described above.
Isolation of bacterial mRNA. Total RNAwas extracted from 13ml of
exponentially growing cultures (optical density at 600 nm [OD600], 0.5 to
0.6), 4.5 ml of stationary-phase cultures at 16 h after inoculation (OD600,
4.5 to 5.5), and 24-ml pooled drug-tolerant cells (equal to the assay mix-
ture after 24 h of treatment with the lytic antibiotic ceftazidime, which
shouldmostly contain RNA from surviving cells), each in triplicate, using
a hot phenol extraction protocol (27). In brief, the cells were harvested by
centrifugation at 4,000 rpm at 4°C for 10 min. The cell pellet was resus-
pended in 1ml of ice-cold resuspension buffer (10mMKCl, 5mMMgCl2,
10 mM Tris [pH 7.4]), and 0.5 ml each was added to preheated tubes
containing 0.4 ml of lysis buffer (0.4 M NaCl, 40 mM EDTA, 1% -mer-
captoethanol, 1% sodium dodecyl sulfate, 20 mM Tris [pH 7.4]) and 0.2
ml of acid phenol (pH 4.5) (catalog no. AM9720; Ambion), using dupli-
cate tubes per sample. The tubes were incubated at 90°C for 5 min and
then chilled on ice for 5 min. Phase separation was achieved by centrifu-
gation at 13,000 rpm for 2min. RNA in the supernatantwas extractedwith
two additional phenol-chloroform extractions and precipitated overnight
at20°C in isopropanol. TheRNAwas pelleted by centrifugation,washed
with 70% ethanol, air-dried for 5 min at room temperature, and resus-
pended in nuclease-free water. Contaminating DNA was removed by
DNase I (Ambion) digestion for 45 min at 37°C, followed by phenol-
chloroform extractions, isopropanol precipitation, and resuspension of
the total RNA in nuclease-free water, as described above. Bacterial mRNA
was enriched using the MICROBExpress kit (catalog no. AM1905; Am-
bion), according to themanufacturer’s recommendations. Duplicates of 5
g of total RNAwere used as an input for each sample, whichwere pooled
in 30 l nuclease-free water after precipitation. Depletion efficiencies
were assessed using a Bioanalyzer platform (Agilent). In all cases, the 23S
and 16S peaks had been reduced from 33 to 45% and 21 to 29% to 2.4 to
6.8% and 0.1 to 1.2%, respectively, of the total area to surface.
Illumina transcriptome sequencing. cDNA libraries were prepared
from the depleted mRNA samples using the TruSeq RNA sample prepa-
ration kit (Illumina), according to the manufacturer’s recommendations
(low-throughput protocol starting with RNA fragmentation). The cDNA
samples were each loaded for hybridization on one lane of an Illumina
flow cell. Seventy-six base-pair sequencing was performed in paired-end
mode with Illumina version 4 SBS reagents using the SCS version 2.6 data
collection software. The raw image data were analyzed using the Illumina
GA2 Pipeline version 1.6, with phasing correctionsmade against the stan-
dard PhiX control lane and all other parameters at their default. The reads
were trimmed to 70 bp and the adaptor sequences filtered, as well as any
reads with90% of bases of scoreQ20. These filtered reads were then
aligned to the genome of B. thailandensis strain E264 (GenBank accession
no. NC_007651 and NC_007650) using the TopHat software package.
The significant analysis of microarrays (SAM) file was then run through
an HTSeq-count script to extract the gene-level counts for the genes, as
defined by the NCBI GenBank/gff file (GenBank-to-gff conversion was
done with BioPerl). Finally, the read-level counts were compared with
DESeq in R, with the in-built statistical analysismethod based on negative
binomial distribution (28). The average numbers of reads of the exponen-
tial- and stationary growth-phase samples were 33,162,087 and
34,752,164, respectively, whereas the average number of reads of the cef-
tazidime survivor samples was 34,336,756. The reads mapped to the 23S,
16S, and 5S genes were excluded from analysis.
Parameter sweeps of mathematical models. Solutions of the two-
state stochastic switching model (see Fig. S4A in the supplemental mate-
rial) were found using the analytical solution provided by Balaban et al.
(9). The details of the results of the parameter searches are covered in the
supplemental material. The numerical simulations of the three-state and
four-state ordinary differential equation (ODE) models presented in Fig.
1B and also in Fig. S5 and S6 in the supplemental material were run in
XPPAUT through aMatLab interface (MatLabR2011b;MathWorks, Inc.,
Natick,MA, USA). The parameter space search algorithms used here start
in the regions of the parameter space and then gradually perturb the
parameters as per a randomwalk by up to 1,000 steps. Each parameter set
was used to calculate the resulting fit to the various objective data sets.
RESULTS
Large percentage of the stationary-phase population ofB. pseu-
domallei andB. thailandensis survives exposure tohighdoses of
ceftazidimeunder clinically relevant conditions. Inside the host,
bacteria able to establish chronic disease are proposed to survive in
an equilibrium of replication and death, similar to the stationary
phase of in vitro cultures (29). With this in mind, we have exam-
ined the ability of stationary-phase bacteria to resist killing by the
-lactam antibiotic ceftazidime, which is commonly used to treat
melioidosis. Using a standardized persister cell assay that was de-
signed to mimic slow-growing oxygen-limited in vivo conditions,
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we challenged cells from the stationary growth phase with antibi-
otics under static incubation (see Materials and Methods). We
determined the survival rates of a panel of Burkholderia strains,
including the pathogenic B. pseudomallei and nonpathogenic B.
thailandensis isolates. The MICs of ceftazidime, measured in a
microtiter tray assay under unshaken conditions, were similar for
the B. thailandensis and B. pseudomallei isolates tested. E. coli
strain MG1655 was included as a control organism in the assay.
We observed similar survivor frequencies of between 102 and
101 with B. pseudomallei and B. thailandensis isolates in the pres-
ence of 100 the MIC of ceftazidime (Fig. 2A). In comparison,
stationary-phase cultures of E. coli K-12 strain MG1655 returned
survivors at a frequency of 107, indicating that Burkholderia sur-
vivors exhibit a higher tolerance to ceftazidime. We chose B. thai-
landensis strain E264, which is often used as a surrogate model for
B. pseudomallei (30), for use in more detailed studies on persister
cell formation.
Tolerance to ceftazidime is oxygendependent.Previouswork
has shown that the oxygen levels in culture medium had a pro-
found effect on the susceptibility of B. pseudomallei to antibiotics
(31) We measured the killing of stationary-phase B. thailandensis
by antibiotics under different oxygen availabilities. We observed
an inverse relationship between ceftazidime killing and atmo-
spheric oxygen levels (Fig. 2B). Killing by ciprofloxacin, a fluoro-
quinolone antibiotic that has been used less frequently to treat
melioidosis (32), was not affected by atmospheric oxygen levels
(Fig. 2B). We obtained similar results by changing the culture
volume, which then changed the dissolved oxygen levels (see text
and Fig. S5 in the supplementalmaterial). Our results are in agree-
ment with the findings by Hamad et al. (31), who demonstrated
that some antibiotics, including ceftazidime, are less effective
against B. pseudomallei cultured under anaerobic conditions.
In order to determine whether the ceftazidime survivors are a
result of decreased drug efficacy under decreased oxygen levels or
whether they can tolerate high doses of antibiotics for prolonged
periods (5, 7, 33), the killing dynamics of stationary-phase cells
exposed to ceftazidime or ciprofloxacin were assessed. We ob-
served biphasic kill curves with a plateau of surviving cells after
exposure to supra-MIC doses of either antibiotic (Fig. 2C). The
initial killing rate was significantly higher for ciprofloxacin (	log
CFU/ml/h
 2.57) than for ceftazidime (	log CFU/ml/h
 0.12).
For both drug exposures, none of the colonies obtained at the 24-h
time points (n,200) grew on LB agar plates supplemented with
50g/ml ceftazidime or 20g/ml ciprofloxacin, showing that the
survivors were not antibiotic-resistant mutants.
The ciprofloxacin survivors differed from the ceftazidime sur-
vivors in their regrowth rate after removal of the antibiotic. The
ceftazidime survivors formed colonies of uniform size on LB agar
plates after 24 h incubation at 37°C, whereas ciprofloxacin survi-
vors required 48 h incubation before visible colonies of variable
sizes were formed on the plates (see Fig. S1 in the supplemental
material).
Transcriptome profiling reveals distinct gene expression
profile of ceftazidime survivors that is similar to that of oxygen-
limited cells. To understand the physiological state of the drug-
tolerant cells, we isolated stationary-phase B. thailandensis cells
that had been grown unshaken in a normal (aerobic) atmosphere
and then survived dosing with 100 the MIC of ceftazidime, and
we sequenced their transcriptomes (see Materials and Methods).
Comparing these to the transcriptome of mid-log-phase cells
(LBML), a total of 1,292 genes showed2-fold higher expression
levels in the ceftazidime survivors, whereas the expression level of
1,171 genes was reduced by2-fold in the ceftazidime survivors.
Compared to stationary-phase cells (LBS), 1,372 genes were up-
regulated in the ceftazidime survivors, and 1,581 genes were
downregulated 2-fold. Despite a similar number of differen-
tially regulated genes, the coefficients of determination (R2) be-
tween the averages of ceftazidime survivors and those of the LBML
FIG 1 Four-state switching model. (A) The extended four-state model with (i) normal aerobic cells that are susceptible to ciprofloxacin and ceftazidime killing
(n), (ii) aerobic cells that are tolerant to ciprofloxacin only (p), (iii) anaerobic cells that are susceptible to ciprofloxacin killing but tolerant to ceftazidime (n), and
(iv) anaerobic cells that are multidrug tolerant (p). The different phenotypic population states are represented by circles and the switching rates between them
by arrows. Under antibiotic treatment, a population state, i, declines (or grows if the drug is ineffective) at a rate ki. The transition rates between n and p and
between n and p are hypothesized to be independent of the oxygen level and also the same (and so both sets are represented by rnp and rpn).However, the switching
rates a and b between n and n or p and p are oxygen dependent. (B) Four-state model fits ceftazidime killing data for the high and low survivor counts observed
using different assay volumes in vitro (B). The four-state model is shown, with a
 0.0561 and b
 0.0301 (1-ml volume, blue circles) and b
 0.05488 (0.5-ml




 0. The switching rates are rnp
 0.02 and rpn
 0.1. These
runs assume that the entire initial population was in the n state.
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samples and LBS samples were 0.751 and 0.004, respectively (see
Fig. S1E and F in the supplemental material). This shows that the
gene expression profile of ceftazidime survivors from stationary-
phase cultures is more similar to the profile of actively growing
cells. The coefficient of determination (R2) between the LBS and
LBML samples was 0.002 (see Fig. S1D in the supplemental mate-
rial). Cluster analysis indicated a low degree of commonality
among the differentially regulated genes, with a high proportion
of genes specifically expressed under one or two conditions (see
Fig. S1G in the supplemental material). Our transcriptome anal-
ysis revealed a reduced level of expression of cell division andDNA
replication genes in persisters, whereas defense mechanisms ap-
peared to be upregulated (Fig. 3A). A comparison of the persister
transcriptome to a recently published transcriptome of B. pseu-
domallei under hypoxia (31) revealed extensive similarities: 58%
of the B. pseudomallei genes with an ortholog in B. thailandensis
that were differentially expressed in cells under hypoxic condi-
tions compared to those in aerobic cultures were differentially
regulated in the same way in B. thailandensis persisters (Fig. 3B).
This included the induction of the denitrification and arginine
deimination (ADI) pathway (see text and Fig. S1H in the supple-
mental material), as well as the induction of F-type ATP synthase
clusters on chromosome II, and a repression of a second ATP
synthase cluster on chromosome I. Thirteen percent of the genes
were inversely regulated in the two data sets. These includedmost
flagellar and chemotaxis genes, which were induced in the stirred
hypoxia samples and repressed in the static ceftazidime-chal-
lenged samples. This suggests that the assay conditions used here
simulate a hypoxic environment and that the anaerobic metabo-
lism of the ceftazidime survivors might relate to their antibiotic
tolerance.
B. pseudomallei narG plays a role in regulating persister cell
frequency. B. thailandensis and B. pseudomallei are obligate re-
spirers and cannot grow under anaerobic conditions in the ab-
sence of an alternate electron acceptor, such as nitrate (31, 34).
The treatment of B. pseudomallei with either ciprofloxacin or cef-
tazidime results in a biphasic kill curve similar to that seen in B.
thailandensis. To test whether anaerobic nitrate respiration (deni-
trification) plays a direct role in persister cell formation, we con-
structed a B. pseudomallei narG deletionmutant (	narG) (see text
and Fig. S9 in the supplemental material). The deletion of narG
prevented anaerobic growth and caused a significant reduction in
nitrate reductase activity under aerobic conditions (see Fig. S9B
and D in the supplemental material). No aerobic growth defect
was seen for the 	narGmutant, which exhibited comparable aer-
obic growth rates to that of the wild type in both M9 minimal
medium and L broth (see Fig. S9C and E in the supplemental
material). Stationary-phase B. pseudomallei wild-type and 	narG
strains were dosed with ceftazidime, aerobically, in either LB me-
dium or LB medium supplemented with 20 mM sodium nitrate.
When stationary-phase wild-type or 	narG bacteria were incu-
bated with antibiotic in LB medium, the numbers of ceftazidime
survivors were similar. However, in LB medium supplemented
with nitrate, the 	narG mutant formed drug-tolerant/persister
cells at a higher frequency than did wild-type B. pseudomallei (Fig.
3C). The survivor frequency for mid-log-phase B. pseudomallei
cultures was also assessed, showing nitrate to have a similar effect
on wild-type but not mutant cultures (Fig. 3D). This points to-
ward a role for anaerobic nitrate respiration and NarGHI in drug
tolerance and susceptibility to ceftazidime.
FIG 2 Persister levels and dynamics in Burkholderiales. (A) Survivor frequen-
cies with various bacterial isolates. Aliquots of bacterial cultures were incu-
bated in the presence of 100 the MIC of ceftazidime, and the surviving
proportion was enumerated after 24 h incubation with antibiotics. Bth, B.
thailandensis; Bps, B. pseudomallei; Eco, E. coli. The MIC of ceftazidime under
atmospheric oxygen levels against each isolate is given in brackets after the
strain designation. (B) Relationship between killing efficiencies of different
antibiotics and oxygen levels. Aliquots of B. thailandensis strain E264 exposed
to 100 the MIC of ceftazidime or 10 the MIC of ciprofloxacin were incu-
bated in 24-well plates in different incubators: aerobic (atmospheric levels of
oxygen), microaerophilic (5% O2), and anaerobic (no oxygen). The survival
frequencies were assessed after 24 h incubation and are defined as the number
of cells that survived the antibiotic treatment (T24) divided by the input CFU
(T0). (C) Time-kill curves with two different antibiotics. Aliquots of bacterial
cultures ofB. thailandensis strain E264were incubated in the presence of 100
the MIC of ceftazidime or 10 the MIC of ciprofloxacin under aerobic con-
ditions. The surviving proportionwas enumerated at the indicated time points
and is plotted on a logarithmic scale over time. The error bars represent the
standard deviation (SD) over the mean from at least three independent exper-
iments.
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Modeling persister cell dynamics using a four-state model
supports the existence of an anaerobic switch. It has been pro-
posed that stochastic switching between a faster growing pheno-
type, which is nontolerant to antibiotics, and a slower growing but
drug-tolerant phenotype can account for the bacterial persistence
phenomenon (9). This two-state switching model is depicted in
Fig. S6A in the supplemental material. While this most parsimo-
nious (i.e., simplest) model fitted some of the data from the orig-
inal experiments, it did not explain the differences in survivors
after exposure to ceftazidime or ciprofloxacin or the dependency
on oxygen availability (Fig. 2B; see also Fig. S5B in the supplemen-
tal material). This suggests that there are at least three distinct
FIG 3 Functional classification of genes that are specifically induced and repressed in ceftazidime survivors and overlap hypoxiamicroarray data. (A) Functional
annotation of genes that were induced in ceftazidime survivors compared to those in mid-log- and/or stationary-phase cells (black bars), and genes that were
repressed in ceftazidime survivors compared to in mid-log- and/or stationary-phase cells (white bars). The functional categories were assigned according to the
Burkholderia Genome Database (66). biogen., biogenetics; posttransl., posttranslation; mod., modification; prot., protein; sec./secr., secretory; ves, vesicle. (B)
Correlation plot of expression ratios of B. pseudomallei (Bps) gene expression levels after 4 h anaerobic growth compared to those in LB mid-log cultures
(microarray data by Hamad et al. [31]) and B. thailandensis (Bth) gene expression levels in ceftazidime survivors compared to those in LB mid-log cultures
(RNA-seq data; this study). Each data point represents a gene that is found in both B. pseudomallei and B. thailandensis (n
 550). Genes that were commonly
upregulated in both anaerobic B. pseudomallei samples and ceftazidime-tolerant B. thailandensis samples are displayed in the top right box, whereas genes that
were commonly downregulated in both anaerobicB. pseudomallei samples and ceftazidime-tolerantB. thailandensis samples are displayed in the bottom left box.
Only genes with an expression of 2 in the hypoxia data set and 1.5 in the persister data set are displayed. (C and D) Ceftazidime survivor frequencies of
stationary-phase (C) ormid-log-phase (D)B. pseudomallei cultures incubated in the presence of 400g/ml ceftazidime in LBmedium (black bars) or LBmedium
supplementedwith orwithout 20mMsodiumnitrate (gray bars). Four independent biological replicates were used eachwith three technical replicates. The error
bars indicate 1 SD. Asterisks denote significant differences between wild-type (wt) B. pseudomallei (K96243) and the 	narG deletion mutant (P 0.01).
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phenotypes with different tolerances to these antibiotics. How-
ever, we found that neither a general three-state stochastic switch-
ing model (see Fig. S6B in the supplemental material) nor a mod-
ified three-state model that incorporates an oxygen-dependent
switch (see Fig. S6C in the supplemental material) captured the
kinetics of persister cell formation for both antibiotics, as de-
scribed in the supplemental material.
We propose a solution by extending the switching model to
four states composed of two separate stochastic switching mech-
anisms (Fig. 1A). The transition rates a and b control the switching
of cells between aerobic and anaerobic metabolism, thereby con-
trolling their tolerance to ceftazidime. These rates are assumed to
depend on the oxygen content of the environment, whereas the
rates rpn and rnp are assumed to be independent of oxygen levels
and control the tolerance of the cells to ciprofloxacin. This four-
state model readily reproduces the invariable proportion of cip-
rofloxacin survivors while allowing oxygen levels to affect the sur-
vivor frequency under ceftazidime exposure over many orders of
magnitude, as indicated by the fit to data in Fig. 1B. We present
this four-state model as the minimal stochastic switching model
necessary to reproduce all the features of the persistence phenom-
enon under different oxygen levels.
Anaerobically adapted drug-tolerant cells can be eliminated
by ciprofloxacin treatment or by introducing oxygen. The
model described above predicts that the majority of the anaerobic
cells are tolerant to ceftazidime but susceptible to ciprofloxacin
(Fig. 1A, population n). To test this, the ceftazidime survivors
were sequentially exposed to different combinations of cipro-
floxacin or ceftazidime. The ceftazidime survivorswere unaffected
by the addition ofmore ceftazidime but were susceptible to killing
by ciprofloxacin, with 273 times fewer survivors (P 0.0001) than
in the cells that had been treated for 48 h with one dose of cefta-
zidime alone (Fig. 4A). In contrast, the ciprofloxacin survivors
were only marginally susceptible to further killing by ciprofloxa-
cin (3 times fewer survivors; P
 0.014) and ceftazidime (4 times
fewer survivors; P 
 0.021), respectively, compared to cells that
had been treated for 48 hwith one dose of ciprofloxacin alone. The
addition of the anaerobically active antibiotic metronidazole to
the ceftazidime and ciprofloxacin survivors did not result in addi-
tional killing (data not shown).
Our model and our data on the formation of drug-tolerant
cells by the 	narG mutant predict that introducing oxygen or
nitrate into the system would activate the aerobic metabolism in
ceftazidime survivors and thus render them susceptible to killing
by ceftazidime. To test this hypothesis, 24-well plates containing
B. thailandensis cells previously challenged statically for 24 h with
ceftazidime or ciprofloxacin were incubated for a further 24 h on
a rotary shaker at 150 rpm. This resulted in a significantly lower
survival frequency (P  0.00001) of 3.8  106 in the case of
ceftazidime-treated samples compared to 2.4  102 after static
incubation for 48 h (Fig. 4B). No difference between the static and
static plus shaking incubation conditions was observed with cip-
rofloxacin. These results indicate that the antibiotic tolerance due
to anaerobic adaptation is reversible, and this type of drug-toler-
ant cells can be eradicated by introducing oxygen into the envi-
ronment or by using antibiotics that can kill cells at low oxygen
levels.
DISCUSSION
Currently, there is much interest in noninherited antibiotic resis-
tance and its role in bacterial disease and environmental survival.
A characteristic feature of this type of resistance is a biphasic an-
tibiotic killing curve, in which a fast initial kill phase is followed by
much slower killing. The surviving cells are tolerant, rather than
resistant (35), to antibiotics. Tolerance may arise as a result of
reduced metabolic activity, lack of growth, and even dormancy of
cells (3, 35, 36), and the term persister cells has been applied to
dormant drug-resistant cells exhibiting a reduction in protein and
ATP synthesis (3, 37–39). However, it is also clear that drug toler-
ance can arise as a consequence of mechanisms other than dor-
mancy (40–42). Consequently, there are increasing numbers of
reports of different types of drug-tolerant cells with different levels
FIG 4 Elimination of anaerobic survivors. (A) Validation of the predicted antibiotic susceptibilities of different anaerobic persister populations was assessed by
adding a second antibiotic to wells with bacteria that were previously challenged for 24 h with ceftazidime (cefta) (black bars) and ciprofloxacin (cipro) (gray
bars). The survival frequencies were assessed after a further 24 h of incubationwith the second antibiotic. Controls that underwent 48 h incubationwith the initial
antibiotic only were included for comparison. (B) Reversal of oxygen-dependent drug tolerance by introduction of oxygen was assessed by incubating 24-well
plates containing bacteria that were previously challenged for 24 h with ceftazidime (black bars) and ciprofloxacin (gray bars), with aeration at 150 rpm. The
survival frequencies were assessed after a further 24 h of incubation with shaking. Controls that underwent 48 h of static incubation were included for
comparison. (A and B) Error bars represent the standard deviation over the mean values from at least three independent experiments.
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of metabolic activity and different patterns of drug tolerance (36,
40, 42–45).
The drug-tolerant cells we characterized retained metabolic
activity, evidenced by our ability to map the transcriptome. This
revealed the upregulation of a range of -lactamases and efflux
pumps in the drug-tolerant cells we isolated (see the data in the
supplemental material). In addition, we found that several genes
associated with the heat shock response were upregulated in the
drug-tolerant cells. Of these, htpX and Hsp20 have been reported
as being expressed in E. coli persister cells (39, 46). Overall, our
findings suggest that the cells we isolated were drug-tolerant cells
as a consequence of a change in their metabolism, rather than
being dormant persister cells.
Against this background, for many decades, it has been known
that compared to log-phase cells, stationary-phase cells are more
resistant to -lactam antibiotics (47). This drug tolerance is con-
sidered to be a consequence of the ability of -lactams to target
growing cells only. Consistent with this, persister cell frequencies
increase as bacterial cultures enter the stationary growth phase (3,
33). Indeed, there are reports that with some species and strains,
the entire stationary-phase culture becomes tolerant to -lactam
antibiotics (33).
In our studies, we have found that Burkholderia exposed to
antibiotics under conditions similar to those likely to be experi-
enced in vivo form drug-tolerant cells at frequencies of 2%,
whereas under similar conditions, we found that E. coli formed
drug-tolerant cells at a frequency of 107. For our studies, we have
used bacteria from the stationary growth phase rather than the
exponential growth phase because there is evidence that bacteria
growing in vivo more closely resemble stationary-phase bacteria.
A study onHaemophilus influenzae demonstrated that cells grown
in animals adopt a physiological state that resembles late station-
ary-phase cultures in vitro (48). Likewise, the gene expression pat-
tern of M. tuberculosis in starved stationary-phase cultures dis-
played features that characterize persistence in vivo, such as entry
into a nonreplicative state and the metabolism of fatty acids (17).
Transcriptional data previously obtained in our lab (49) also in-
dicated that global gene expression in B. pseudomallei recovered
from the lungs of infectedmice is very similar to that of cells grown
to stationary phase in vitro.
Another important finding from our work is that oxygen levels
play a role in regulating the frequencies of drug-tolerant cells. An
increasing number of studies show that oxygen-depleted environ-
ments constitute a common environment for bacterial pathogens
that are able to establish chronic disease and also for environmen-
tal bacteria (50–54). It has been reported that the growth of Burk-
holderia bacteria under anaerobic conditions had a marked influ-
ence on the MICs of some antibiotics (31). In this study, we show
that atmospheric oxygen levels influence the frequencies of cells
tolerant to ceftazidime (but not ciprofloxacin). Our results also
indicate that oxygen did not regulate E. coli persister cell frequen-
cies, and this might reflect a difference in metabolic capacity. It
will now be important to assess how oxygen levels influence per-
sister cell frequency in other bacterial species.
The transcriptomes of bacteria that survived dosing with cef-
tazidime in unshaken broths and in a normal atmosphere revealed
that their metabolism is more similar to cells grown under anaer-
obic conditions than to that of stationary-phase cells. This likely
reflects a combination of the settling out of cells and the formation
of an oxygen gradient in the medium. It is possible that the cells
that settle out are in a relatively anaerobic environment, where
they are unable to grow due to the lack of a terminal electron
acceptor, such as oxygen or nitrate. It has been shown that even
nongrowing bacteria require some form of cellular energy and
redox balance to stay viable (55). Therefore, it is not surprising
that survivors show upregulation of a range of genes encoding
proteins required for anaerobic nitrate respiration (denitrifica-
tion), including the NarGHI complex, which is required for the
utilization of nitrate as a terminal electron acceptor.
The increased susceptibility of wild-type B. pseudomallei cells
to ceftazidime with the addition of nitrate, which was not seen in
the 	narG mutant, implicates anaerobic nitrate respiration and
NarGHI in drug tolerance. We propose that the increase in cefta-
zidime susceptibility with the addition of nitrate is due to the
generation of a proton motive force (PMF) by NarGHI. Previous
studies have implicated the generation of PMF by the addition of
metabolites, such as nitrate, in antibiotic susceptibility (56, 57).
Recently, a low abundance of NarGH in E. coli has been linked to
aminoglycoside and cephalosporin (including ceftazidime) resis-
tance, thought to be due to a lowered PMF (58). Increased aera-
tion during the persister assay (Fig. 4B) resulted in an altered
susceptibility of B. thailandensis cells to ceftazidime, potentially
due to an increase in aerobic respiration. Both the addition of
nitrate and the increased aeration during the persister assay are
likely to initiate an active electron transport pathway, either via
denitrification or oxidative phosphorylation, renderingBurkhold-
eria bacteria susceptible to ceftazidime action. In summary, our
work that has shown that drug tolerance is governed by anaerobic
adaptation but not respiration.
Interestingly, the ceftazidime survivors obtained in our assay
setup were not killed by the addition of metronidazole. This anti-
biotic has been shown to kill anaerobically adapted B. pseudomal-
lei (31), and we observed the killing of 95% of the population of B.
thailandensis within 24 h if incubated under strict anaerobic con-
ditions in plain LB broth (data not shown). This suggests that
either the anaerobic adaptation of the ceftazidime survivors was
only partial or that the residual oxygen, or even the presence of
ceftazidime, in the static incubation assay interfered with the ac-
tivity of metronidazole. The effect of metronidazole in a model of
chronic melioidosis remains to be elucidated.
We also used mathematical modeling to support our experi-
mental results, and this modeling suggests that the different types
of drug-tolerant cells we have seen result from the actions of two
intertwined switches, one which involves oxygen-basedmetabolic
switching. This modeling also predicted that the introduction of
oxygen would eliminate persisters, and we confirmed this experi-
mentally. Together with our results, these findings show that in
many bacteria, including Burkholderia, drug tolerance is not nec-
essarily due to the presence of a subpopulation of metabolically
inactive cells (7, 40).
Our findings suggest new approaches to the control ofmelioid-
osis. Despite intensive antibiotic treatment, themortality rates for
melioidosis can be 40 to 50% in areaswhere the disease is endemic,
and recurring disease occurs in 5 to 25% of cases (15, 59–61).
Granuloma-like abscesses formed during chronic melioidosis
might provide a hypoxic environment (15, 16, 62, 63), and bacte-
ria that reside in hypoxic abscesses would not be targeted by cef-
tazidime treatment. Our results might suggest that ciprofloxacin
or a combination therapy of ceftazidime and ciprofloxacin would
be highly effective for the treatment of melioidosis, but previous
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studies have shown a variable efficacy for ciprofloxacin (32). This
likely reflects the finding that some strains ofB. pseudomallei show
intermediate resistance to ciprofloxacin (64). Our finding that
ceftazidime survivors lose their antibiotic tolerance after the ad-
dition of nitrate or the reintroduction of oxygen to the system
might be another lead for improved success of chronicmelioidosis
treatment, through the elevation of respiratory activity. Hyper-
baric oxygen treatment (HBO) is already successfully used in cases
of chronic osteomyelitis and necrotizing infections (65). The ef-
fect of HBO or ozonized oxygen on melioidosis patients remains
to be tested.
In summary, the findings of this study provide new insight into
the mechanisms by which bacteria resist killing by antibiotics by
modifying their metabolic state. It remains to be elucidated if
these results and the oxygen-dependent switch in persister cell
formation apply more generally to other bacterial species.
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